You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞信下調上海醫藥(02607.HK)目標價至18元 評級降至「中性」
阿思達克 09-07 15:21
瑞信發表研究報告指,上海醫藥(02607.HK)中期收入及經調整淨利潤按年升21%及16%,大致符合預期,但受分銷及零售銷售所拖累,期內毛利率按年收窄1.3個百分點。 公司早前宣布引入雲南白藥為戰略投資者,交易目前正在進行中,但籌集所得資金用途及未來雙方戰略規劃等未有更進一步細節。 至於與康希諾(06185.HK)合作的疫苗生產設施一期正在建返中,預期可於明年投產,項目設計年產量達2億至2.5億劑。 瑞信將上海醫藥的評級由「跑贏大市」降至「中性」,指出對與雲南白藥的戰略合作效用及康希諾疫苗項目長期利潤貢獻感到擔憂,基於上半年業績表現,將2021至2022年經調整淨利潤預測下調0.3%及0.4%,2023年則被上調2.7%,又指去年下半年基數較高,並將目標價由20元降至18元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account